Found 57 articles for: "tinea pedis"
Evaluation of a Moisturizing Cream with 20% Urea for Keratosis Pilaris
January 2024 | Volume 23 | Issue 1 | Original Article | 1274 | Copyright © January 2024
Background: Keratosis pilaris (KP) is a benign dermatosis consisting of folliculocentric keratotic papules or pustules with surrounding erythema, often on proximal extensor surfaces of extremitie...
Read MoreOnychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
October 2023 | Volume 22 | Issue 10 | Original Article | 1040 | Copyright © October 2023
Background: Onychomycosis represents the highest proportion of nail disorders seen in clinical practice. Onychomycosis management may differ amongst specialties, with impact on patien...
Read MoreFULL SUPPLEMENT: Optimizing Transungal Efficacy at the Site of the Infection With Efinaconazole
September 2023 | Volume 22 | Issue 9 | Department | SF378719s5 | Copyright © September 2023
Onychomycosis is a prevalent condition affecting the United States and global population. Treatment options are limited, with only 3 topical anti-fungal medications garnering approval in the US w...
Read MoreIndividual Article: Updated Review of Topical Pharmaceuticals and Complementary and Alternative Medications for the Treatment of Onychomycosis in Both General and Special Populations in the United States
September 2023 | Volume 22 | Issue 9 | Supplement Individual Articles | SF378719 | Copyright © September 2023
Onychomycosis is a prevalent condition affecting the United States and global population. Treatment options are limited, with only 3 topical anti-fungal medications garnering approval in the US w...
Read MoreVerrucous Psoriasis: Rare Variant and Novel Treatment
August 2023 | Volume 22 | Issue 8 | Case Reports | 826 | Copyright © August 2023
Xenopoulou D, Pochat C, Greco E. Verrucous psoriasis: rare variant and novel treatment. J Drugs Dermatol. 2023;22(8):826-827. doi:10.36849/JDD.C6874R1...
Read MorePoroma in a Patient With Fitzpatrick Type V Skin
July 2023 | Volume 22 | Issue 7 | Case Reports | 690 | Copyright © July 2023
This case detailing a poroma in Fitzpatrick Type V skin presents gross, dermatoscopic, and histopathologic images that have not been adequately represented in the literature. Diagnosing poroma ca...
Read MoreCurrent Issues in Global Onychomycosis Management
April 2022 | Volume 21 | Issue 4 | Original Article | 371 | Copyright © April 2022
Introduction: Onychomycoses occur worldwide and are complex infections to treat. Diagnosis with standard culture methods has been problematic. Treatment historically used oral monothe...
Read MoreTherapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US
October 2021 | Volume 20 | Issue 10 | Original Article | 1076 | Copyright © October 2021
Background: Onychomycosis affects around 14% of individuals in North America and Europe and is undertreated. Treatment is challenging as toenail growth can take 12–18 months, th...
Read MoreSafety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients
September 2020 | Volume 19 | Issue 9 | Original Article | 867 | Copyright © September 2020
Background: Pediatric onychomycosis management is challenging as there are limited treatment options. The objective of this study was to evaluate efinaconazole 10% topical solution in...
Read MoreUse of In-Office Preparations by Dermatologists for the Diagnosis of Cutaneous Fungal Infections
August 2019 | Volume 18 | Issue 8 | Original Article | 798 | Copyright © August 2019
Cutaneous fungal infections account for millions of office visits per year, yet their varied presentations often lead to misdiagnosis. If dermatology clinics are Clinical Laboratory Improvement Amendm...
Read MoreTavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study
February 2019 | Volume 18 | Issue 2 | Original Article | 190 | Copyright © February 2019
BACKGROUND: This study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of tavaborole in pediatric patients. Study Design: In this open-label, single-arm study, ...
Read MoreA Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment
October 2018 | Volume 17 | Issue 10 | Original Article | 1100 | Copyright © October 2018
BACKGROUND: Nitric oxide (NO), a free radical gas, is endogenously produced in human cells. In high concentration, NO neutralizes many disease-causing microbes. The topical investigational drug SB206 ...
Read MoreA Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis
August 2018 | Volume 17 | Issue 8 | Original Article | 888 | Copyright © August 2018
Background: Tinea pedis, or athlete’s foot, is a superficial, skin infection caused by dermatophytes. It is usually topically treated. Nitric oxide is endogenously produced in humans and has a varie...
Read MoreProximal Subungual Onychomycosis in the Immunocompetent: A Case Report and Review of the Literature
April 2018 | Volume 17 | Issue 4 | Case Reports | 475 | Copyright © April 2018
Proximal subungual onychomycosis (PSO), which predominantly involves the nail plate from the proximal nail fold, is the rarest form of onychomycosis. Classically associated with an immunocompromised s...
Read MoreClinical Insights About Onychomycosis and Its Treatment: A Consensus
March 2018 | Volume 17 | Issue 3 | Original Article | 253 | Copyright © March 2018
BACKGROUND: Recently, experience and knowledge have been gained using effective topical treatment for onychomycosis, a difficult-to-treat infection. METHODS: This project aims to help understand and ...
Read MoreTreatment of Signs and Symptoms (Pruritus) of Interdigital Tinea Pedis With Econazole Nitrate Foam, 1%
February 2018 | Volume 17 | Issue 2 | Original Article | 229 | Copyright © February 2018
BACKGROUND: Tinea pedis is the most common dermatophyte infection. Treatment is critical to alleviate pruritic symptoms, to reduce the risk for secondary bacterial infection, and to limit the spread o...
Read MoreIs Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?
February 2018 | Volume 17 | Issue 2 | Original Article | 175 | Copyright © February 2018
BACKGROUND: Onychomycosis is a common disease that remains a difficult disorder to treat despite the introduction of new topical agents; and not all patients are cured. Clinical experience leads us to...
Read MoreLong-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole
December 2017 | Volume 16 | Issue 12 | Original Article | 1269 | Copyright © December 2017
Background: Onychomycosis is a common disease that remains difficult to treat despite the introduction of new topical agents. Clinical trials on efinaconazole and tavaborole included 48 weeks’ daily...
Read MoreTavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects
October 2017 | Volume 16 | Issue 10 | Original Article | 1016 | Copyright © October 2017
Toenail onychomycosis is a chronic fungal infection that often requires prolonged treatment in order to effectively manage pathogenic organisms and obtain a clear nail. Traditionally, certain clinical...
Read MorePediatric Onychomycosis: The Emerging Role of Topical Therapy
February 2017 | Volume 16 | Issue 2 | Original Article | 105 | Copyright © February 2017
Fungal infection of the nails is an increasingly recognized disease in infants and children. However, it can be difficult to distinguish clinically from other nail dystrophies. In addition, many mi...
Read MoreMedia and other results for: "tinea pedis"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
